Purple AI has been selected as a 2025 Deep Tech Tips (TIPS) company by the Ministry of SMEs and Startups.
DeepTech TIPS is an advanced track of the TIPS program, a joint effort between the government and private investors to discover and support startups in disruptive technologies. The government provides approximately 1.5 billion won in R&D funding, three times the amount of support provided by the standard TIPS program. Furthermore, the evaluation criteria, including technological and commercial viability, are stringent.
Purple AI is a startup jointly founded by the AI Healthcare team at SK AX (formerly SK C&C) and professors of radiology at Seoul National University Hospital and Ajou University Hospital. The company's flagship solution, "Medical Insight Plus Cerebral Hemorrhage," is a software-based medical device (SaMD) that assists medical professionals in diagnosing cerebral hemorrhage using brain CT scans. Various empirical studies have demonstrated its effectiveness in improving diagnostic accuracy and reducing treatment times. Its competitiveness has been proven by receiving approval as a Class 3 medical device from the Ministry of Food and Drug Safety, designation as an innovative medical technology by the Ministry of Health and Welfare, and approval from the US FDA.
Based on this TIPS support, Purple AI is pursuing expansion into a video and multimodal AI lineup that supports the end-to-end stroke treatment workflow.
Purple AI's selection of Deep Tech Tips was made through investment and recommendation by Big Basin Capital, the operator of Tips.
Pil-gu Yoon, CEO of Big Basin Capital, said, “Purple AI’s stroke AI solutions are demonstrating the world’s best performance among similar medical devices, and are also making meaningful progress in terms of commercialization, such as through insurance coverage.” He explained that this was the reason he recommended Purple AI.
Purple AI CEO Park Byung-jun stated, “We believe that being selected as a DeepTech Tips company is a recognition of our technology, medical domain expertise, and market expansion potential. We will focus on completing our comprehensive stroke AI platform and achieving full-scale global success.”
You must be logged in to post a comment.